Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin added to metformin for nonalcoholic fatty liver disease in adults with type 2 diabetes
IRCT20220115053717N1Phase 3Completed
- Sponsor
- Urmia University of Medical Sciences
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of empagliflozin in metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Urmia University of Medical Sciences. Primary endpoints: Fasting blood sugar, Low-density lipoprotein cholesterol and 7 more. Started Jul 2022; status: completed.
02
Drugs
empagliflozin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20220115053717N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220115053717N1.